YTHDC2 and metabolic dysfunction-associated steatotic liver disease: Furthermore, YTHDC2 was shown to be significantly reduced in multiple obese mouse models and nonalcoholic fatty liver disease (NAFLD) patients, and knockdown of YTHDC2 led to excessive triglycerides (TGs) accumulation in hepatocytes, via inhibiting the expressions of lipogenic genes including sterol regulatory element-binding protein 1c, fatty acid synthase and acetyl-CoA carboxylase 1222.